Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Coiled-coil domain-containing protein 180 (CCDC180) is a nuclear-localized protein comprising 1,701 amino acids, encoded by the *CCDC180* gene on human chromosome 9q22.33. It contains two overlapping coiled-coil regions and two domains of unknown function (DUF4455 and DUF4456). CCDC180 is predominately expressed in testes, with lower expression seen in other tissues including trachea and eye. Its transcription is regulated by multiple factors, notably SRY and SOX transcription factors, hinting at a role in sex determination and possibly transcription regulation. CCDC180 interacts with several cell cycle and signaling proteins such as Y box binding protein 1, Erb-B2 receptor tyrosine kinase 2, and retinoblastoma 1. Although a SNP (S995C) in CCDC180 is linked to Behçet's disease, its precise pathogenic mechanism remains unknown. There is no evidence to date for direct drug targeting, or identification of approved/well-studied inhibitors, agonists, or modulators.
Not applicable (no therapeutics target this protein)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Coiled-coil domain-containing protein 180 (CCDC180).